| Attribute |
Value |
| 52 Week Change |
1.1571851 |
| Address1 |
1,111 Kane Concourse |
| Address2 |
Suite 301 |
| All Time High |
26.69 |
| All Time Low |
4.72 |
| Ask |
13.64 |
| Ask Size |
1 |
| Average Daily Volume10 Day |
9,870 |
| Average Daily Volume3 Month |
19,260 |
| Average Volume |
19,260 |
| Average Volume10Days |
9,870 |
| Beta |
1.448 |
| Bid |
13.5 |
| Bid Size |
1 |
| Book Value |
1.59 |
| City |
Bay Harbor Islands |
| Compensation As Of Epoch Date |
1,735,603,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
13.26 |
| Current Ratio |
2.49 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,774,915,200 |
| Day High |
13.58 |
| Day Low |
13.09 |
| Debt To Equity |
108.094 |
| Dividend Date |
1,719,705,600 |
| Earnings Timestamp End |
1,755,259,200 |
| Earnings Timestamp Start |
1,754,909,940 |
| Ebitda |
-65,560,000 |
| Ebitda Margins |
-1.03633 |
| Enterprise To Ebitda |
-6.515 |
| Enterprise To Revenue |
6.752 |
| Enterprise Value |
427,153,984 |
| Eps Trailing Twelve Months |
-0.863 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,718,323,200 |
| Exchange |
NCM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
13.11082 |
| Fifty Day Average Change |
0.14918041 |
| Fifty Day Average Change Percent |
0.01137842 |
| Fifty Two Week Change Percent |
115.718506 |
| Fifty Two Week High |
14.64 |
| Fifty Two Week High Change |
-1.3800001 |
| Fifty Two Week High Change Percent |
-0.0942623 |
| Fifty Two Week Low |
5.49 |
| Fifty Two Week Low Change |
7.7700005 |
| Fifty Two Week Low Change Percent |
1.4153007 |
| Fifty Two Week Range |
5.49 - 14.64 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,510,669,800,000 |
| Five Year Avg Dividend Yield |
14.44 |
| Float Shares |
22,145,703 |
| Free Cashflow |
-47,286,376 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
78 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.48113 |
| Gross Profits |
30,437,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.0 |
| Held Percent Institutions |
0.0 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Dividend Date |
1,718,323,200 |
| Last Dividend Value |
0.195 |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. |
| Long Name |
Fortress Biotech, Inc. |
| Market |
us_market |
| Market Cap |
71,177,960 |
| Market State |
CLOSED |
| Max Age |
86,400 |
| Message Board Id |
finmb_61731337 |
| Most Recent Quarter |
1,767,139,200 |
| Net Income To Common |
-1,882,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Open |
13.53 |
| Operating Cashflow |
-65,777,000 |
| Operating Margins |
-0.29784 |
| Phone |
781 652 4500 |
| Previous Close |
13.12 |
| Price Hint |
2 |
| Price To Book |
8.3396225 |
| Price To Sales Trailing12 Months |
1.1251298 |
| Profit Margins |
0.10773 |
| Quick Ratio |
2.198 |
| Quote Source Name |
Delayed Quote |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
0.14000034 |
| Regular Market Change Percent |
1.0670757 |
| Regular Market Day High |
13.58 |
| Regular Market Day Low |
13.09 |
| Regular Market Day Range |
13.09 - 13.58 |
| Regular Market Open |
13.53 |
| Regular Market Previous Close |
13.12 |
| Regular Market Price |
13.26 |
| Regular Market Time |
1,776,456,000 |
| Regular Market Volume |
13,095 |
| Return On Assets |
-0.26617 |
| Return On Equity |
-1.0874 |
| Revenue Growth |
0.063 |
| Revenue Per Share |
2.267 |
| Sand P52 Week Change |
0.36506534 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
56,679,500 |
| Shares Short |
195 |
| Shares Short Previous Month Date |
1,772,150,400 |
| Shares Short Prior Month |
3,251 |
| Short Name |
Fortress Biotech, Inc. - 9.375% |
| Short Ratio |
0.03 |
| Source Interval |
15 |
| State |
FL |
| Symbol |
FBIOP |
| Total Cash |
79,381,000 |
| Total Cash Per Share |
2.465 |
| Total Debt |
67,216,000 |
| Total Revenue |
63,262,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-0.863 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
9.529915 |
| Two Hundred Day Average Change |
3.7300854 |
| Two Hundred Day Average Change Percent |
0.39140806 |
| Type Disp |
Equity |
| Volume |
13,095 |
| Website |
https://www.fortressbiotech.com |
| Zip |
33,154 |